Baxter International (BAX) Competitors

$18.34 +0.55 (+3.06%)

Closing price 03:59 PM Eastern

Extended Trading

$18.33 -0.01 (-0.03%)

As of 07:59 PM Eastern

BAX vs. AMN, DVA, RMD, DXCM, and STE

Should you buy Baxter International stock or one of its competitors? MarketBeat compares Baxter International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Baxter International include AMN Healthcare Services (AMN), DaVita (DVA), ResMed (RMD), DexCom (DXCM), and STERIS (STE). These companies are all part of the "medical" sector.

How does Baxter International compare to AMN Healthcare Services?

Baxter International (NYSE:BAX) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Baxter International has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

In the previous week, AMN Healthcare Services had 8 more articles in the media than Baxter International. MarketBeat recorded 9 mentions for AMN Healthcare Services and 1 mentions for Baxter International. AMN Healthcare Services' average media sentiment score of 0.00 beat Baxter International's score of -0.34 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AMN Healthcare Services	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AMN Healthcare Services has a net margin of -0.95% compared to Baxter International's net margin of -9.70%. AMN Healthcare Services' return on equity of 18.01% beat Baxter International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.70%	16.15%	5.24%
AMN Healthcare Services	-0.95%	18.01%	5.19%

90.2% of Baxter International shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 0.2% of Baxter International shares are owned by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

AMN Healthcare Services has lower revenue, but higher earnings than Baxter International. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.24B	0.84	-$957M	-$2.13	N/A
AMN Healthcare Services	$2.73B	0.38	-$95.70M	-$0.87	N/A

Baxter International presently has a consensus target price of $19.91, suggesting a potential upside of 8.59%. AMN Healthcare Services has a consensus target price of $25.29, suggesting a potential downside of 6.08%. Given Baxter International's higher probable upside, equities analysts plainly believe Baxter International is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
AMN Healthcare Services	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.44

Summary

AMN Healthcare Services beats Baxter International on 11 of the 17 factors compared between the two stocks.

How does Baxter International compare to DaVita?

Baxter International (NYSE:BAX) and DaVita (NYSE:DVA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

90.2% of Baxter International shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 0.2% of Baxter International shares are owned by company insiders. Comparatively, 1.5% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, DaVita had 5 more articles in the media than Baxter International. MarketBeat recorded 6 mentions for DaVita and 1 mentions for Baxter International. DaVita's average media sentiment score of 0.51 beat Baxter International's score of -0.34 indicating that DaVita is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DaVita	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

DaVita has a net margin of 5.65% compared to Baxter International's net margin of -9.70%. Baxter International's return on equity of 16.15% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.70%	16.15%	5.24%
DaVita	5.65%	-270.37%	4.87%

Baxter International has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, DaVita has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

DaVita has higher revenue and earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.24B	0.84	-$957M	-$2.13	N/A
DaVita	$13.64B	0.92	$746.80M	$10.78	18.04

Baxter International currently has a consensus target price of $19.91, indicating a potential upside of 8.59%. DaVita has a consensus target price of $199.17, indicating a potential upside of 2.42%. Given Baxter International's higher probable upside, equities research analysts plainly believe Baxter International is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

Summary

DaVita beats Baxter International on 12 of the 16 factors compared between the two stocks.

How does Baxter International compare to ResMed?

Baxter International (NYSE:BAX) and ResMed (NYSE:RMD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

ResMed has a net margin of 27.44% compared to Baxter International's net margin of -9.70%. ResMed's return on equity of 25.35% beat Baxter International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.70%	16.15%	5.24%
ResMed	27.44%	25.35%	18.69%

ResMed has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.24B	0.84	-$957M	-$2.13	N/A
ResMed	$5.15B	5.88	$1.40B	$10.37	20.05

Baxter International pays an annual dividend of $0.04 per share and has a dividend yield of 0.2%. ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.2%. Baxter International pays out -1.9% of its earnings in the form of a dividend. ResMed pays out 23.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 13 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Baxter International has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, ResMed has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

90.2% of Baxter International shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 0.2% of Baxter International shares are owned by insiders. Comparatively, 0.7% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Baxter International presently has a consensus price target of $19.91, indicating a potential upside of 8.59%. ResMed has a consensus price target of $286.18, indicating a potential upside of 37.66%. Given ResMed's stronger consensus rating and higher possible upside, analysts plainly believe ResMed is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, ResMed had 12 more articles in the media than Baxter International. MarketBeat recorded 13 mentions for ResMed and 1 mentions for Baxter International. ResMed's average media sentiment score of 1.06 beat Baxter International's score of -0.34 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ResMed	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ResMed beats Baxter International on 17 of the 20 factors compared between the two stocks.

How does Baxter International compare to DexCom?

Baxter International (NYSE:BAX) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

DexCom has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.24B	0.84	-$957M	-$2.13	N/A
DexCom	$4.66B	5.54	$836.30M	$2.34	28.61

DexCom has a net margin of 19.31% compared to Baxter International's net margin of -9.70%. DexCom's return on equity of 33.33% beat Baxter International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.70%	16.15%	5.24%
DexCom	19.31%	33.33%	13.19%

90.2% of Baxter International shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 0.2% of Baxter International shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Baxter International currently has a consensus target price of $19.91, indicating a potential upside of 8.59%. DexCom has a consensus target price of $82.21, indicating a potential upside of 22.79%. Given DexCom's stronger consensus rating and higher probable upside, analysts clearly believe DexCom is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

Baxter International has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, DexCom has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

In the previous week, DexCom had 35 more articles in the media than Baxter International. MarketBeat recorded 36 mentions for DexCom and 1 mentions for Baxter International. DexCom's average media sentiment score of 0.68 beat Baxter International's score of -0.34 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	17 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

DexCom beats Baxter International on 16 of the 17 factors compared between the two stocks.

How does Baxter International compare to STERIS?

Baxter International (NYSE:BAX) and STERIS (NYSE:STE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

STERIS has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.24B	0.84	-$957M	-$2.13	N/A
STERIS	$5.94B	3.54	$782.30M	$7.93	27.04

Baxter International has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, STERIS has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

In the previous week, STERIS had 5 more articles in the media than Baxter International. MarketBeat recorded 6 mentions for STERIS and 1 mentions for Baxter International. STERIS's average media sentiment score of 0.63 beat Baxter International's score of -0.34 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
STERIS	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Baxter International presently has a consensus target price of $19.91, indicating a potential upside of 8.59%. STERIS has a consensus target price of $275.67, indicating a potential upside of 28.55%. Given STERIS's stronger consensus rating and higher probable upside, analysts plainly believe STERIS is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
STERIS	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

STERIS has a net margin of 13.18% compared to Baxter International's net margin of -9.70%. Baxter International's return on equity of 16.15% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.70%	16.15%	5.24%
STERIS	13.18%	14.15%	9.52%

90.2% of Baxter International shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.2% of Baxter International shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Baxter International pays an annual dividend of $0.04 per share and has a dividend yield of 0.2%. STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.2%. Baxter International pays out -1.9% of its earnings in the form of a dividend. STERIS pays out 31.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has increased its dividend for 20 consecutive years. STERIS is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

STERIS beats Baxter International on 15 of the 18 factors compared between the two stocks.

Get Baxter International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BAX vs. The Competition

Export

Metric	Baxter International	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$9.19B	$8.31B	$6.25B	$22.83B
Dividend Yield	0.22%	2.53%	2.80%	4.11%
P/E Ratio	-8.61	12.99	17.54	26.70
Price / Sales	0.84	8.04	531.21	23.81
Price / Cash	3.13	16.91	43.09	24.68
Price / Book	1.57	3.93	9.81	4.61
Net Income	-$957M	$224.05M	$3.55B	$1.07B
7 Day Performance	2.34%	-2.56%	-2.07%	-1.81%
1 Month Performance	-1.82%	-3.78%	-3.90%	-2.17%
1 Year Performance	-41.78%	0.27%	29.39%	20.97%

Baxter International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BAX Baxter International	2.1135 of 5 stars	$18.34 +3.1%	$19.91 +8.6%	-43.9%	$9.19B	$11.24B	N/A	37,500
AMN AMN Healthcare Services	1.6839 of 5 stars	$28.94 +1.1%	$25.29 -12.6%	+27.6%	$1.11B	$2.73B	N/A	2,664	Analyst Upgrade
DVA DaVita	3.5878 of 5 stars	$199.73 0.0%	$199.17 -0.3%	+37.5%	$12.82B	$13.64B	18.53	78,000
RMD ResMed	4.786 of 5 stars	$203.97 +1.0%	$286.18 +40.3%	-19.0%	$29.41B	$5.15B	19.67	10,600
DXCM DexCom	4.5119 of 5 stars	$65.09 +5.6%	$82.21 +26.3%	-23.9%	$23.78B	$4.66B	27.82	11,000	Trending News Analyst Forecast Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BAX) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Baxter International (BAX) Competitors

BAX vs. AMN, DVA, RMD, DXCM, and STE

How does Baxter International compare to AMN Healthcare Services?

Summary

How does Baxter International compare to DaVita?

Summary

How does Baxter International compare to ResMed?

Summary

How does Baxter International compare to DexCom?

Summary

How does Baxter International compare to STERIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BAX vs. The Competition

Baxter International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Baxter International (BAX) Competitors

BAX vs. AMN, DVA, RMD, DXCM, and STE

How does Baxter International compare to AMN Healthcare Services?

Which has more risk and volatility, BAX or AMN?

Does the media favor BAX or AMN?

Is BAX or AMN more profitable?

Do institutionals & insiders hold more shares of BAX or AMN?

Which has preferable earnings & valuation, BAX or AMN?

Do analysts recommend BAX or AMN?

Summary

How does Baxter International compare to DaVita?

Do insiders and institutionals have more ownership in BAX or DVA?

Does the media prefer BAX or DVA?

Is BAX or DVA more profitable?

Which has more risk and volatility, BAX or DVA?

Which has stronger earnings and valuation, BAX or DVA?

Do analysts rate BAX or DVA?

Summary

How does Baxter International compare to ResMed?

Is BAX or RMD more profitable?

Which has preferable earnings and valuation, BAX or RMD?

Is BAX or RMD a better dividend stock?

Which has more volatility and risk, BAX or RMD?

Do institutionals and insiders believe in BAX or RMD?

Do analysts rate BAX or RMD?

Does the media prefer BAX or RMD?

Summary

How does Baxter International compare to DexCom?

Which has preferable earnings & valuation, BAX or DXCM?

Is BAX or DXCM more profitable?

Do institutionals and insiders have more ownership in BAX or DXCM?

Do analysts rate BAX or DXCM?

Which has more volatility & risk, BAX or DXCM?

Does the media prefer BAX or DXCM?

Summary

How does Baxter International compare to STERIS?

Which has better earnings & valuation, BAX or STE?

Which has more risk & volatility, BAX or STE?

Does the media favor BAX or STE?

Do analysts recommend BAX or STE?

Is BAX or STE more profitable?

Do institutionals & insiders have more ownership in BAX or STE?

Is BAX or STE a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BAX vs. The Competition

Baxter International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools